Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901678 | 0.86 | TSHR (0.81) | TSHRCYP4A11CYP4F2TDP1MEN1 | |
| SCHEMBL4312014 | 0.85 | LOXL2 (0.53) | TSHRLOXL2CYP4A11CYP4F2TDP1 | |
| SCHEMBL1198228 | 0.84 | LOXL2 (0.63) | TSHRLOXL2CYP4A11CYP4F2TDP1 | |
| SCHEMBL19134100 | 0.83 | TSHR (0.57) | TSHRCYP4A11CYP4F2TDP1MEN1 | |
| SCHEMBL14010060 | 0.82 | TSHR (0.70) | TSHRCYP4A11CYP4F2TDP1MEN1 | |
| SCHEMBL13800480 | 0.80 | CA1 (0.70) | TSHRLOXL2CYP4A11CYP4F2TDP1 | |
| SCHEMBL5646360 | 0.79 | LOXL2 (0.58) | TSHRLOXL2CYP4A11CYP4F2TDP1 | |
| SCHEMBL317876 | 0.79 | TSHR (0.66) | TSHRTDP1KMT2AKLK7 | |
| SCHEMBL5175026 | 0.79 | TSHR (0.76) | TSHRMEN1KMT2ACA2KLK7 | |
| SCHEMBL9626909 | 0.79 | TSHR (0.70) | TSHRTDP1MEN1KMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708279-B2 | 2-acylaminothiazoles for the treatment of cancer | UNIVERSITÁ DEGLI STUDI DI MILANO—BICOCCA (IT) | 2017-07-18 | — | — | US | disclosed |
| US-9708279-B2 | 2-acylaminothiazoles for the treatment of cancer | UNIVERSITÁ DEGLI STUDI DI MILANO—BICOCCA (IT) | 2017-07-18 | — | — | US | disclosed |
| US-9708279-B2 | 2-acylaminothiazoles for the treatment of cancer | UNIVERSITÁ DEGLI STUDI DI MILANO—BICOCCA (IT) | 2017-07-18 | — | — | US | disclosed |
| EP-3016948-B1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA (IT) | 2017-05-10 | — | — | EP | disclosed |
| EP-3016948-B1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA (IT) | 2017-05-10 | — | — | EP | disclosed |
| US-20160257658-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITE' CLAUDE BERNARD LYON 1 (FR) | 2016-09-08 | — | — | US | disclosed |
| US-20160257658-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITE' CLAUDE BERNARD LYON 1 (FR) | 2016-09-08 | — | — | US | disclosed |
| US-20160257658-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITE' CLAUDE BERNARD LYON 1 (FR) | 2016-09-08 | — | — | US | disclosed |
| EP-3016948-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | Università Degli Studi Di Milano - Bicocca (IT) | 2016-05-11 | — | — | EP | disclosed |
| WO-2015001024-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015001024-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2015-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257658-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | ALK, ERBB2, ABL1 | TSHR 3358/4885LOXL2 1101/4885CYP4A11 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.